Recent Story Posts
Community
India’s Efforts to Help End Hepatitis C Starts with Prison Population
Innovation
Thumbi Ndung’u on Thinking Beyond Lifelong Treatment in HIV
Culture
‘Inside the Innovation:' Oncology Leaders Discuss Life at Gilead
Recent Press Releases
-
November 29, 2021
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS -
November 23, 2021
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
For more information, contact us.
Phone:
1-800-GILEAD-5 (1-800-445-3235)
1-800-GILEAD-5 (1-800-445-3235)